Skip to main content

Tweets

Downward Effects! Real world data from 22,934 UK #RA pts starting 1st b/tsDMARD shows DAS remission/LDA achieved in 17% following 1st line, 13% 2nd, & 8-13% with 3rd thru 6th DMARD. (LDA in 29% 1st line, 23% 2nd, 17–22% 3rd thru 6th) https://t.co/cZt0BvhK6I https://t.co/blemgbDoN8
Dr. John Cush @RheumNow ( View Tweet )
4 years 3 months ago
Despite COVID, revenues for half of top 20 pharma companies grew 10-40% in 2021 Revenues (billions) 1 J&J $97 2 Pfizer $81 3 Roche $62 4 Abbvie $56 5 Novartis $51 6 Merck $48 7 BMS $46 8 GSK $46 9 Sanofi $44 10 AZ $37 https://t.co/rSovxIXOId https://t.co/GuKIBYoML6
Dr. John Cush @RheumNow ( View Tweet )
4 years 3 months ago
Males respond better than females? Ixekizumab trials in #PSA - 676 pts in Two Phase 3 RCTs - females had lower response rates than males in all measures (ACR20/50/70; MDA; DAPSA) F had ⬆️HAQ, enthesitis, but ⬇️CRP https://t.co/Om8CwbmlgN https://t.co/872E7HGOp2
Dr. John Cush @RheumNow ( View Tweet )
4 years 3 months ago
QD Clinic - PsA Lessons from the Clinic LFT Elevations may be considered differently in PsA patients QD Clinic is sponsored by RheumNow's PsA All the Way Campaign in April 2022 https://t.co/dCaWx5OTda https://t.co/bRTVqQ4ZJj
Dr. John Cush @RheumNow ( View Tweet )
4 years 3 months ago
Dr. Laura Coates discusses Precision Medicine in PsA. https://t.co/ttKHZDGjyC https://t.co/XwahihZyGH
Dr. John Cush @RheumNow ( View Tweet )
4 years 3 months ago
The value of COVID Vaccine after COVID infection - Vax Effx after COVID=445% after 2 doses & 58% after booster during Delta COVID. During Omicron, 35% effect after 2 doses and 68% after a booster dose - best protection conferred by booster https://t.co/VXi70r2nS3 https://t.co/Oeuet3pudD
Dr. John Cush @RheumNow ( View Tweet )
4 years 3 months ago
QD Clinic - PsA Lessons from the Clinic Reasons why PsA patient can lose biologic efficacy and what to do about it QD Clinic is sponsored by RheumNow's PsA All the Way Campaign in April 2022 https://t.co/Bxy1G68rU9 https://t.co/CLe9SHfRQJ
Dr. John Cush @RheumNow ( View Tweet )
4 years 3 months ago
Combined Clinics for PsA Rheums and derms have long worked together in the management of our patients, but the idea of directly collaborating in a single clinic space was novel at the time. Over the years, it has become my favorite clinic of the week. https://t.co/uY1mZtlvaV https://t.co/5AZ2z2kSVG
Dr. John Cush @RheumNow ( View Tweet )
4 years 3 months ago
Comparison of Tofa, ADA, PBO in OPAL #PSA studies - median time to HAQ response better for Tofa & ADA (30d) vs PBO (>112d), but Tofa had faster Fatigue response (31 vs 90+D). MDA response time same between Tofa v ADA #PSAlways https://t.co/f48Of7bEjN https://t.co/KvfQUbLwCH
Dr. John Cush @RheumNow ( View Tweet )
4 years 3 months ago
NPF COVID-19 report from AAD mtg shows #PSA pts on systemic Rx were not at risk of hospitalization or severe COVID-1 based on US claims data. Also TNFi, IL-17, IL-23 Rx not affect on Vax Ab responses; less hosp (36%) w/ TNFi https://t.co/ekvu0mMvrn https://t.co/Qogm1Vx5hF
Dr. John Cush @RheumNow ( View Tweet )
4 years 3 months ago
How long does a good response last to a biologic? How and When to distinguish between flares and intercurrent illness. QD Clinic is sponsored by RheumNow's PsA All the Way Campaign in April 2022 https://t.co/ZIWQysY5dd https://t.co/RZrS6FfUTV
Dr. John Cush @RheumNow ( View Tweet )
4 years 3 months ago
SLE study from BC, Canada shows that among 3062 incident #SLE patients 96% received antimalarial (AM) Rx with only 40% adherent. Over a 6.4 yr F/U, 242 (8%) died. AM adherence was assoc w/ a 71% and 83% lower risk of death https://t.co/S9LsDaSZNx https://t.co/lFWZJTh367
Dr. John Cush @RheumNow ( View Tweet )
4 years 3 months ago
×